ICU Medical (STU:IC7) Notes Receivable: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IC7 ICU Medical Inc STU:IC7
80 GF Score
Price €158.00
GF Value €105.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is ICU Medical Notes Receivable?

ICU Medical STU:IC7 80 Notes Receivable is €0 Mil as of Jun. 2026. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ICU Medical's Notes Receivable for the quarter that ended in Jun. 2026 was €0 Mil.

ICU Medical Notes Receivable Historical Data

* Premium members only.

The historical data trend for ICU Medical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ICU Medical Notes Receivable Chart

ICU Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ICU Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:IC7
80GF Score
ICU Medical Inc STU:IC7
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ICU Medical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0 Mil mean?
ICU Medical (STU:IC7) has a Notes Receivable of €0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on ICU Medical and its competitors.
Is ICU Medical's Notes Receivable too high?
ICU Medical's current Notes Receivable is €0 Mil. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Notes Receivable compare to NVST and MMSI?
ICU Medical's Notes Receivable of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on ICU Medical and its competitors. ICU Medical's current Notes Receivable is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Notes Receivable is €0 Mil. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Notes Receivable is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ICU Medical (STU:IC7) Overvalued in 2026?

Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued. The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79. GuruFocus considers ICU Medical to be Significantly Overvalued.

Key valuation signals for STU:IC7:

  • Notes Receivable: €0 Mil
  • GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ICU Medical Business Description

Other Exchanges ICUI:USA
Address 951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score

Get the complete analysis for STU:IC7

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.00
Price
€105.79
GF Value